Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDNF | P23560 | 3/20 | 0.47 |
| ▸ | PTN | P21246 | 2/20 | 0.47 |
| ▸ | MDK | P21741 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 4/20 | 0.44 |
| ▸ | CD69 | Q07108 | 1/20 | 0.40 |
| ▸ | FGF1 | P05230 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13321920 | 0.87 | F10 (0.40) | BDNFPTNMDKF10CD69 | |
| SCHEMBL14208653 | 0.83 | BDNF (0.65) | BDNFPTNMDKF10LGALS3 | |
| SCHEMBL25785583 | 0.83 | BDNF (0.62) | BDNFPTNMDKF10FGF1 | |
| SCHEMBL17002053 | 0.81 | CA2 (0.47) | BDNFPTNMDKF10CD69 | |
| SCHEMBL27097990 | 0.80 | BDNF (0.57) | BDNFPTNMDKF10FGF1 | |
| SCHEMBL30498721 | 0.79 | BDNF (0.51) | BDNFPTNMDKF10CD69 | |
| SCHEMBL30089435 | 0.78 | BDNF (0.53) | BDNFPTNMDKF10CD69 | |
| SCHEMBL13130296 | 0.78 | BDNF (0.46) | BDNFPTNMDKF10CD69 | |
| SCHEMBL18022304 | 0.77 | CD69 (0.47) | CD69LGALS3LGALS1LGALS7; LGALS7B | |
| SCHEMBL11997499 | 0.76 | F10 (0.40) | BDNFPTNMDKF10CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394781-B2 | Disaccharides for the treatment of tendons, ligaments, and bones | BIOIBERICA, S.A. (ES) | 2013-03-12 | — | — | US | disclosed |
| US-20100129331-A1 | DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES | BIOIBERICA, S.A. (ES) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129331-A1 | DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES | IGFBP1, FGF1, IGFBP2 | BDNF 151/4885PTN 494/4885MDK 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.